PBLA Insider Trading Activity and SEC Form 4 Filings
PBLA insider trading summary
No open-market insider purchases or sales of Panbela Therapeutics, Inc. (PBLA) have been reported on SEC Form 4 in the past 12 months.
Latest PBLA insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Nov 8, 2023 | Goldman Sachs Group Inc | 10% Owner | Sell | $52K (72,874 @ $0.71) |
| Nov 8, 2023 | Goldman Sachs & Co. LLC | 10% Owner | Sell | $52K (72,874 @ $0.71) |
| Jan 30, 2023 | Jennifer K. Simpson | President and CEO | Buy | $0 (4,444 @ $0.00) |
| Jan 30, 2023 | Susan Horvath | V.P. of Finance & CFO | Buy | $0 (4,444 @ $0.00) |
| Oct 4, 2022 | Michael T. Cullen | Director | Buy | $0 (165,000 @ $0.00) |
| Oct 4, 2022 | Jeffrey E. Jacob | Director | Buy | $0 (33,000 @ $0.00) |
| Oct 4, 2022 | Donald Robert Schemel | Director | Buy | $0 (200,000 @ $0.00) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.